Results 191 to 200 of about 227,135 (339)

Is there a correlation between structure and anticoagulant action of sulfated galactans and sulfated fucans? [PDF]

, 2002
M. S. Pereira, Fábio Rabelo Melo, Paulo A.S. Mourão   +2 more
openalex   +1 more source

CYP2C19 genotype testing for clopidogrel: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)

British Journal of Clinical Pharmacology, EarlyView.
Clopidogrel, an antiplatelet agent, is currently licensed in the United Kingdom for the prevention and treatment of atherothrombotic events in cerebrovascular disease, coronary artery disease and peripheral arterial disease. Clopidogrel requires metabolic activation by the cytochrome P450 enzyme CYP2C19 to be effective.
Cinzia Dello Russo, Iain Frater, Rebecca Kuruvilla, Stefanie Lip, Hannah O'Neill, Kerry Burke, Vicky Chaplin, Alexander S. F. Doney, Salim Elyas, Nicholas Greaves, Sophie Harding, David Hargroves, Judith Hayward, Dyfrig A. Hughes, Tom A. T. Hughes, Sree Kondapally, Patrick Mok, Aaron Peace, Imran Rafi, Simon Ray, Vicky Stinton, Luigi Venetucci, Munir Pirmohamed   +22 more
wiley   +1 more source

Aspirin as a viable alternative to oral anticoagulants for VTE prevention after hip arthroplasty: a meta-analysis of randomized clinical trials. [PDF]

BMC Surg
Zhang G, Huang L, Xu X, Yang Y, Ying X, Han D.   +5 more
europepmc   +1 more source

The use of direct oral anticoagulants after pulmonary embolism regarding the bleeding risk in the countries without reimbursement Results from the Regional Pulmonary Embolism Registry [PDF]

Sandra Pekovic, D Tasić, Marija Benić, Boris Džudović, Sonja Šalinger-Martinović, Jeftić, Vladimir Miloradović, Tamara Preradović Kovačević, B Božović, Irena Mitevska, Bojan Mitrović, Aleksandar Nešković, Slobodan Obradović   +12 more
openalex   +1 more source

Geriatric Elements and Oral Anticoagulant Prescribing in Older Atrial Fibrillation Patients: SAGE‐AF [PDF]

, 2019
Jane S. Saczynski, Saket Sanghai, Catarina I. Kiefe, Darleen Lessard, Francesca Marino, Molly E. Waring, David C. Parish, Robert Helm, Felix Sogade, Robert J. Goldberg, Jerry H. Gurwitz, Weijia Wang, Tanya Mailhot, Benita A. Bamgbade, Bruce Barton, David D. McManus   +15 more
openalex   +1 more source

Comparative effectiveness and safety of oral anticoagulants in patients with atrial fibrillation using antiarrhythmic drugs: An international cohort study

British Journal of Clinical Pharmacology, EarlyView.
Aim Our international cohort study assessed the comparative effectiveness and safety of direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs) among patients with non‐valvular atrial fibrillation (NVAF) using antiarrhythmic drugs. Methods Using the United Kingdom's (UK's) Clinical Practice Research Datalink Aurum and Québec claims data, we
Fabian Maximilian Meinert, Jenny Dimakos, Ying Cui, Kristian B. Filion, Christel Renoux, Antonios Douros   +5 more
wiley   +1 more source

Anticoagulation Treatment in Patients with Septic Thrombophlebitis of the Internal Jugular Vein. [PDF]

West J Emerg Med
Senda A, Fushimi K, Morishita K.
europepmc   +1 more source

Phénomène de résistance aux anticoagulants chez les rongeurs ravageurs des plantations de palmier à huile en Indonésie : Session 44 : Ecotoxicologie évolutive [PDF]

, 2010
Andru, Julie, Benoit, Etienne, Caliman, Jean-Pierre, Chaval, Yannick, Cosson, Jean François, Lasseur, Romain   +5 more
core  

Hypnotic doses of fazamorexant induced less impairment on balance and cognition than zolpidem in healthy younger and elderly individualse

British Journal of Clinical Pharmacology, EarlyView.
Aims Fazamorexant is a dual orexin receptor antagonist being developed for the treatment of insomnia. This study aims to determine the dose‐exposure‐response relationship of single‐dose fazamorexant vs. zolpidem in young adult and elderly healthy Chinese volunteers. Methods This single‐centre, randomized, double‐blind, double‐dummy, placebo‐ and active‐
Chen Xia, Huang Xingxing, Jin Lu, Wang Ruwei   +3 more
wiley   +1 more source

Is a case of one thromboembolic event one too many? [PDF]

Interv Pain Med
Levi D, Levin J.
europepmc   +1 more source